Base de dados : MEDLINE
Pesquisa : C18.452.950.565 [Categoria DeCS]
Referências encontradas : 7082 [refinar]
Mostrando: 1 .. 10   no formato [Detalhado]

página 1 de 709 ir para página                         

  1 / 7082 MEDLINE  
              next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:29441917
[Ti] Título:Analysis of the necessity of serum electrolyte monitoring for up to eight weeks after the completion of anti-epidermal growth factor receptor antibody administration.
[So] Source:Pharmazie;71(7):402-407, 2016 Jul 07.
[Is] ISSN:0031-7144
[Cp] País de publicação:Germany
[La] Idioma:eng
[Ab] Resumo:Electrolyte disturbances are a known side effect of cetuximab (cmab) and panitumumab (pmab) administration and monitoring is recommended during and for at least 8 weeks after pmab administration. However, the recommended duration of electrolyte monitoring is not stated on the cmab package insert in the EU or Japan and no previous studies have investigated the appropriate monitoring period for cmab and pmab. We retrospectively investigated electrolyte levels in 16 cmab-treated patients and 7 pmab-treated patients between 1 June 2009 and 31 December 2014. The mean minimum levels of serum magnesium, potassium, and calcium were analyzed in these patients before administration (baseline) and in period A (during administration), period B (time of the last administration), period C (from the completion of administration to 4 weeks after), and period D (from 4-8 weeks after administration). Hypokalemia persisted until period D in 1 cmab-treated patient. Hypomagnesemia persisted until period D in two pmab-treated patients and hypokalemia persisted until period D in 1 pmab-treated patient. In addition, the serum magnesium levels in periods A, B, and C in the cmab-treated patients were significantly lower than the baseline level (P < 0.05). In pmabtreated patients, the serum magnesium levels in periods A, C, and D, and the serum calcium levels in periods A, B, and C were lower than the baseline levels (P < 0.05). These findings indicate that it is necessary to monitor electrolyte levels for at least 8 weeks after the completion of administration of cmab or pmab.
[Mh] Termos MeSH primário: Anticorpos Monoclonais/efeitos adversos
Cetuximab/efeitos adversos
Eletrólitos/sangue
Receptor do Fator de Crescimento Epidérmico/antagonistas & inibidores
Desequilíbrio Hidroeletrolítico/induzido quimicamente
[Mh] Termos MeSH secundário: Adulto
Idoso
Anticorpos Monoclonais/uso terapêutico
Anticorpos Monoclonais Humanizados/efeitos adversos
Anticorpos Monoclonais Humanizados/uso terapêutico
Cálcio/sangue
Cetuximab/uso terapêutico
Feminino
Seres Humanos
Hipopotassemia/sangue
Hipopotassemia/induzido quimicamente
Deficiência de Magnésio/sangue
Deficiência de Magnésio/induzido quimicamente
Masculino
Meia-Idade
Monitorização Fisiológica
Estudos Retrospectivos
Desequilíbrio Hidroeletrolítico/sangue
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Antibodies, Monoclonal); 0 (Antibodies, Monoclonal, Humanized); 0 (Electrolytes); 6A901E312A (panitumumab); EC 2.7.10.1 (Receptor, Epidermal Growth Factor); PQX0D8J21J (Cetuximab); SY7Q814VUP (Calcium)
[Em] Mês de entrada:1803
[Cu] Atualização por classe:180308
[Lr] Data última revisão:
180308
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:180215
[St] Status:MEDLINE
[do] DOI:10.1691/ph.2016.6537


  2 / 7082 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:29203252
[Au] Autor:Yamazaki H; Kondo T; Aoki K; Yamashita K; Takaori-Kondo A
[Ad] Endereço:Department of Hematology and Oncology, Graduate School of Medicine, Kyoto University, Kyoto, Japan.
[Ti] Título:Occurrence and improvement of renal dysfunction and serum potassium abnormality during administration of liposomal amphotericin B in patients with hematological disorders: A retrospective analysis.
[So] Source:Diagn Microbiol Infect Dis;90(2):123-131, 2018 Feb.
[Is] ISSN:1879-0070
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:Liposomal amphotericin B (L-AMB) has the potential to cause two major adverse events, renal dysfunction and serum potassium abnormality; however, appropriate clinical management of these events remains unclear. We retrospectively analyzed data regarding 128 hematology patients who received L-AMB in our institute and examined the association between clinical characteristics and renal dysfunction or serum potassium abnormality. We found that the median weight-normalized dose of L-AMB was 2.69mg/kg and the median administration period was 16days. The overall occurrence rates of renal dysfunction and hypokalemia were 55.7% and 76.6%, respectively. Multivariate analysis revealed that pre-existing renal dysfunction (P=0.017) and concomitant use of nephrotoxic (P<0.0001) or antifungal drugs (P=0.012) were independent risk factors for renal dysfunction. A higher infusion volume did not mitigate the risk of renal dysfunction. Hypokalemia occurred significantly less often in men (P=0.028) and in patients who concomitantly used nephrotoxic drugs (P=0.013). Approximately 40% of the adverse events were improved at 30days after L-AMB termination and there was no significant association between these adverse events improvement and L-AMB dosage or infusion volume. Of note, hyperkalemia was observed in more patients who received allogeneic hematopoietic stem cell transplantation (P=0.0303) and concomitant treatment with nephrotoxic drugs (P=0.0281). These results suggest that imprudent reduction of L-AMB dose or redundant intravenous infusion may have minimal benefit for critical patients with suspected invasive fungal infection.
[Mh] Termos MeSH primário: Anfotericina B/efeitos adversos
Antifúngicos/efeitos adversos
Hiperpotassemia
Hipopotassemia
Nefropatias
[Mh] Termos MeSH secundário: Adolescente
Adulto
Idoso
Idoso de 80 Anos ou mais
Anfotericina B/administração & dosagem
Anfotericina B/uso terapêutico
Antifúngicos/administração & dosagem
Antifúngicos/uso terapêutico
Feminino
Doenças Hematológicas/complicações
Seres Humanos
Hiperpotassemia/induzido quimicamente
Hiperpotassemia/epidemiologia
Hiperpotassemia/prevenção & controle
Hipopotassemia/induzido quimicamente
Hipopotassemia/epidemiologia
Hipopotassemia/prevenção & controle
Nefropatias/induzido quimicamente
Nefropatias/epidemiologia
Nefropatias/prevenção & controle
Testes de Função Renal
Masculino
Meia-Idade
Micoses/complicações
Micoses/tratamento farmacológico
Micoses/prevenção & controle
Estudos Retrospectivos
Fatores de Risco
Adulto Jovem
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Antifungal Agents); 0 (liposomal amphotericin B); 7XU7A7DROE (Amphotericin B)
[Em] Mês de entrada:1802
[Cu] Atualização por classe:180209
[Lr] Data última revisão:
180209
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:171206
[St] Status:MEDLINE


  3 / 7082 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
[PMID]:28745843
[Au] Autor:Ashurst J; Sergent SR; Wagner BJ; Kim J
[Ad] Endereço:Director of Emergency Medicine Residency Research, Duke Lifepoint Conemaugh Memorial Medical Center, Johnstown, PA.
[Ti] Título:Evidence-based management of potassium disorders in the emergency department [digest].
[So] Source:Emerg Med Pract;18(11 Suppl Points & Pearls):S1-S2, 2016 Nov 22.
[Is] ISSN:1559-3908
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:Hypokalemia and hyperkalemia are the most common electrolyte disorders managed in the emergency department. The diagnosis of these potentially life-threatening disorders is challenging due to the often vague symptomatology a patient may express, and treatment options may be based upon very little data due to the time it may take for laboratory values to return. This review examines the most current evidence with regard to the pathophysiology, diagnosis, and management of potassium disorders. In this review, classic paradigms, such as the use of sodium polystyrene and the routine measurement of serum magnesium, are tested, and an algorithm for the treatment of potassium disorders is discussed. [Points & Pearls is a digest of Emergency Medicine Practice].
[Mh] Termos MeSH primário: Serviço Hospitalar de Emergência
Medicina Baseada em Evidências
Hiperpotassemia
Hipopotassemia
[Mh] Termos MeSH secundário: Desequilíbrio Ácido-Base/diagnóstico
Desequilíbrio Ácido-Base/fisiopatologia
Desequilíbrio Ácido-Base/terapia
Resinas de Troca de Cátion/uso terapêutico
Gerenciamento Clínico
Testes Hematológicos/métodos
Seres Humanos
Hiperpotassemia/diagnóstico
Hiperpotassemia/fisiopatologia
Hiperpotassemia/terapia
Hipopotassemia/diagnóstico
Hipopotassemia/fisiopatologia
Hipopotassemia/terapia
Magnésio/sangue
Desequilíbrio Hidroeletrolítico/diagnóstico
Desequilíbrio Hidroeletrolítico/fisiopatologia
Desequilíbrio Hidroeletrolítico/terapia
[Pt] Tipo de publicação:JOURNAL ARTICLE; REVIEW
[Nm] Nome de substância:
0 (Cation Exchange Resins); I38ZP9992A (Magnesium)
[Em] Mês de entrada:1801
[Cu] Atualização por classe:180117
[Lr] Data última revisão:
180117
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170727
[St] Status:MEDLINE


  4 / 7082 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28930854
[Au] Autor:Wang A; Li X; Dookhun MN; Zhang T; Xie P; Cao Y
[Ad] Endereço:aDepartment of Cardiology, Gansu Provincial Hospital bSchool of Clinical Medicine, Gansu University of Chinese Medicine, Lanzhou cDepartment of Intensive Care, Minhang Hospital, Fudan University, Shanghai dDepartment of Cardiology, the First Affiliated Hospital, Nanjing Medical University, Nanjing, China.
[Ti] Título:A female patient with hypokalaemia-induced J wave syndrome: An unusual case report.
[So] Source:Medicine (Baltimore);96(38):e8098, 2017 Sep.
[Is] ISSN:1536-5964
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:RATIONALE: Prominent J waves can be seen in life-threatening cardiac arrhythmias such as Brugada syndrome, early repolarization syndrome, and ventricular fibrillation. We herein present an unusual case report of hypokalemia-induced J wave syndrome and ST (a part of ECG) segment elevation. PATIENTS CONCERNS: A 52-year-old woman with chief complaints of chest pain for 2 hours and diarrhea showed a marked hypokalemia (2.8 mmol/L) and slightly elevated creatine kinase-MB (CK-MB) (57.5 U/L). The electrocardiographic (ECG) recording was normal upon admission and computed tomography (CT) aorta angiography excluded an aorta dissection. ECG done 17 hours after admission showed ST segment elevation and elevated J wave in leads II, III and aVF, and fusion of T and U wave in all leads. DIAGNOSIS: We first thought that the diagnosis of this patient was acute myocardial syndrome. INTERVENTION: Potassium chloride and oflocaxin treatment was given to the patient. OUTCOMES: Laboratory test showed the level of serum potassium ion increased to 3.4 mmol/L and CK-MB did not have any significant change. The infusion of potassium chloride-induced disappearance of the elevated J wave, although QT (a part of ECG) intervals were still longer than that upon admission. LESSONS: This case tells us that hypokalaemia might induce J wave and elevated ST segments which should be distinguished from acute myocardial syndrome.
[Mh] Termos MeSH primário: Arritmias Cardíacas/diagnóstico
Arritmias Cardíacas/etiologia
Hipopotassemia/complicações
[Mh] Termos MeSH secundário: Antibacterianos/uso terapêutico
Arritmias Cardíacas/tratamento farmacológico
Dor no Peito/etiologia
Diagnóstico Diferencial
Eletrocardiografia
Feminino
Seres Humanos
Hipopotassemia/tratamento farmacológico
Levofloxacino/uso terapêutico
Meia-Idade
Infarto do Miocárdio/diagnóstico
Cloreto de Potássio/uso terapêutico
Soluções para Reidratação/uso terapêutico
[Pt] Tipo de publicação:CASE REPORTS; JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Anti-Bacterial Agents); 0 (Rehydration Solutions); 660YQ98I10 (Potassium Chloride); 6GNT3Y5LMF (Levofloxacin)
[Em] Mês de entrada:1709
[Cu] Atualização por classe:171015
[Lr] Data última revisão:
171015
[Sb] Subgrupo de revista:AIM; IM
[Da] Data de entrada para processamento:170921
[St] Status:MEDLINE
[do] DOI:10.1097/MD.0000000000008098


  5 / 7082 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28917345
[Au] Autor:Hassan C; Condorelli G; Repici A
[Ad] Endereço:Endoscopy and Cardiology Department, IRCCS Istituto Clinico Humanitas, Rozzano, Milano, Italy.
[Ti] Título:Bowel preparation for colonoscopy and hypokalemia: at the heart of the problem!
[So] Source:Gastrointest Endosc;86(4):680-683, 2017 10.
[Is] ISSN:1097-6779
[Cp] País de publicação:United States
[La] Idioma:eng
[Mh] Termos MeSH primário: Colonoscopia
Hipopotassemia
[Mh] Termos MeSH secundário: Catárticos
Seres Humanos
Polietilenoglicóis
[Pt] Tipo de publicação:EDITORIAL; COMMENT
[Nm] Nome de substância:
0 (Cathartics); 30IQX730WE (Polyethylene Glycols)
[Em] Mês de entrada:1710
[Cu] Atualização por classe:171031
[Lr] Data última revisão:
171031
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170918
[St] Status:MEDLINE


  6 / 7082 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
[PMID]:28866977
[Au] Autor:Mårtensson J; Bailey M; Venkatesh B; Pilcher D; Deane A; Abdelhamid YA; Crisman M; Verma B; MacIsaac C; Wigmore G; Shehabi Y; Suzuki T; French C; Orford N; Kakho N; Prins J; Ekinci EI; Bellomo R
[Ad] Endereço:Department of Intensive Care, Austin Hospital, Melbourne, VIC, Australia.
[Ti] Título:Intensity of early correction of hyperglycaemia and outcome of critically ill patients with diabetic ketoacidosis.
[So] Source:Crit Care Resusc;19(3):266-273, 2017 Sep.
[Is] ISSN:1441-2772
[Cp] País de publicação:Australia
[La] Idioma:eng
[Ab] Resumo:OBJECTIVES: To determine the impact of the intensity of early correction of hyperglycaemia on outcomes in patients with diabetic ketoacidosis (DKA) admitted to the intensive care unit. METHODS: We studied adult patients with DKA admitted to 171 ICUs in Australia and New Zealand from 2000 to 2013. We used their blood glucose levels (BGLs) in the first 24 hours after ICU admission to determine whether intensive early correction of hyperglycemia to ≤ 180 mg/dL was independently associated with hypoglycaemia, hypokalaemia, hypo-osmolarity or mortality, compared with partial early correction to > 180 mg/dL as recommended by DKA-specific guidelines. RESULTS: Among 8553 patients, intensive early correction of BGL was applied to 605 patients (7.1%). A greater proportion of these patients experienced hypoglycaemia (20.2% v 9.1%; P < 0.001) and/or hypo-osmolarity (29.4% v 22.0%; P < 0.001), but not hypokalaemia (16.7% v 15.6%; P = 0.47). Overall, 11 patients (1.8%) in the intensive correction group and 112 patients (1.4%) in the partial correction group died (P = 0.42). However, after adjustment for illness severity, partial early correction of BGL was independently associated with a lower risk of hypoglycaemia (odds ratio [OR], 0.38; 95% CI, 0.30-0.48; P < 0.001), lower risk of hypo-osmolarity (OR, 0.80; 95% CI, 0.65-0.98; P < 0.03) and lower risk of death (OR, 0.44; 95% CI, 0.22-0.86; P = 0.02). CONCLUSIONS: In a large cohort of patients with DKA, partial early correction of BGL according to DKA-specific guidelines, when compared with intensive early correction of BGL, was independently associated with a lower risk of hypoglycaemia, hypo-osmolarity and death.
[Mh] Termos MeSH primário: Estado Terminal/terapia
Cetoacidose Diabética/tratamento farmacológico
Hiperglicemia/tratamento farmacológico
Hipoglicemia/induzido quimicamente
Hipoglicemiantes/uso terapêutico
Hipopotassemia/induzido quimicamente
[Mh] Termos MeSH secundário: Adulto
Glicemia/metabolismo
Protocolos Clínicos
Cetoacidose Diabética/metabolismo
Feminino
Seres Humanos
Hiperglicemia/metabolismo
Unidades de Terapia Intensiva
Tempo de Internação
Modelos Logísticos
Masculino
Meia-Idade
Mortalidade
Análise Multivariada
Razão de Chances
Concentração Osmolar
Planejamento de Assistência ao Paciente
Estudos Retrospectivos
Índice de Gravidade de Doença
Desequilíbrio Hidroeletrolítico/induzido quimicamente
Adulto Jovem
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Blood Glucose); 0 (Hypoglycemic Agents)
[Em] Mês de entrada:1710
[Cu] Atualização por classe:171031
[Lr] Data última revisão:
171031
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170905
[St] Status:MEDLINE


  7 / 7082 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28823583
[Au] Autor:Perrone D; Afridi F; King-Morris K; Komarla A; Kar P
[Ad] Endereço:University of Central Florida/HCA Graduate Medical Education Consortium Internal Medicine Residency Program, Department of Internal Medicine, University of Central Florida College of Medicine, Orlando, FL. Electronic address: dana.perrone@ucf.edu.
[Ti] Título:Proximal Renal Tubular Acidosis (Fanconi Syndrome) Induced by Apremilast: A Case Report.
[So] Source:Am J Kidney Dis;70(5):729-731, 2017 Nov.
[Is] ISSN:1523-6838
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:Apremilast is a recently developed phosphodiesterase 4-inhibitory medication approved for use to treat psoriasis and psoriatic arthritis. We report a case of Fanconi syndrome and proximal renal tubular acidosis that was associated with this medication. Our patient was started on treatment with apremilast 2 weeks before his admission. On arrival, laboratory test results were significant for hypokalemia, hyperchloremic metabolic acidosis, low uric acid concentration, positive urine anion gap, and proteinuria, which resolved on discontinuation of the drug. Two months after the hospitalization, he was restarted on apremilast therapy; 17 days after resumption, the patient was admitted for similar laboratory values, which again improved when apremilast treatment was discontinued. After discharge, laboratory values remained normal without long-term electrolyte repletion. Proximal renal tubular acidosis (Fanconi syndrome) with quick correction of electrolyte concentrations on discontinuation of the drug was diagnosed. Our patient lacked evidence of other causes. Our patient fulfilled criteria associated with this disease and responded well off treatment with the offending agent. Literature review did not reveal prior cases associated with this medication.
[Mh] Termos MeSH primário: Acidose Tubular Renal/induzido quimicamente
Anti-Inflamatórios não Esteroides/efeitos adversos
Artrite Psoriásica/tratamento farmacológico
Síndrome de Fanconi/induzido quimicamente
Talidomida/análogos & derivados
[Mh] Termos MeSH secundário: Acidose/sangue
Acidose/induzido quimicamente
Acidose Tubular Renal/sangue
Idoso
Síndrome de Fanconi/sangue
Seres Humanos
Hipopotassemia/sangue
Hipopotassemia/induzido quimicamente
Masculino
Proteinúria/induzido quimicamente
Talidomida/efeitos adversos
Ácido Úrico/sangue
[Pt] Tipo de publicação:CASE REPORTS; JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Anti-Inflammatory Agents, Non-Steroidal); 268B43MJ25 (Uric Acid); 4Z8R6ORS6L (Thalidomide); UP7QBP99PN (apremilast)
[Em] Mês de entrada:1710
[Cu] Atualização por classe:171030
[Lr] Data última revisão:
171030
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170822
[St] Status:MEDLINE


  8 / 7082 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
[PMID]:28806047
[Au] Autor:Elliott TL
[Ad] Endereço:Womack Army Medical Center, 2817 Reilly Road, Fort Bragg, NC 28310.
[Ti] Título:Electrolytes: Potassium Disorders.
[So] Source:FP Essent;459:21-28, 2017 Aug.
[Is] ISSN:2159-3000
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:Hypokalemia (ie, potassium levels less than 3.5 mEq/L) occurs in fewer than 1% of healthy individuals, but is present in up to 20% of hospitalized patients, 40% of patients taking diuretics, and 17% of patients with cardiovascular conditions. Hypokalemia often is asymptomatic; symptoms are more common in older adults. Common symptoms are cardiac arrhythmias and muscle weakness or pain. Management consists of intravenous potassium replacement during cardiac monitoring for patients with marked symptoms, echocardiogram (ECG) abnormalities, or severe hypokalemia (ie, level less than 3.0 mEq/L). Oral replacement is appropriate for asymptomatic patients with less severe hypokalemia. Hyperkalemia (ie, level greater than 5.5 mEq/L) also can cause cardiac arrhythmias and muscle symptoms. Urgent management is warranted for patients with potassium levels of 6.5 mEq/L or greater, if ECG manifestations of hyperkalemia are present regardless of potassium levels, or if severe muscle symptoms occur. Urgent management includes intravenous calcium, intravenous insulin, and inhaled beta agonists. Hemodialysis can be used in urgent situations. For patients with less severe hyperkalemia, renal elimination drugs sometimes are used, as are gastrointestinal elimination drugs. For all patients with hypokalemia or hyperkalemia, drug regimens should be reevaluated and, when possible, hypokalemia- or hyperkalemia-causing drugs should be discontinued.
[Mh] Termos MeSH primário: Hiperpotassemia/fisiopatologia
Hipopotassemia/fisiopatologia
[Mh] Termos MeSH secundário: Administração por Inalação
Administração Intravenosa
Agonistas Adrenérgicos beta/uso terapêutico
Arritmias Cardíacas/etiologia
Arritmias Cardíacas/fisiopatologia
Cálcio/uso terapêutico
Eletrocardiografia
Seres Humanos
Hiperpotassemia/complicações
Hiperpotassemia/terapia
Hipoglicemiantes/uso terapêutico
Hipopotassemia/complicações
Hipopotassemia/terapia
Insulina/uso terapêutico
Cloreto de Potássio/uso terapêutico
Diálise Renal
[Pt] Tipo de publicação:JOURNAL ARTICLE; REVIEW
[Nm] Nome de substância:
0 (Adrenergic beta-Agonists); 0 (Hypoglycemic Agents); 0 (Insulin); 660YQ98I10 (Potassium Chloride); SY7Q814VUP (Calcium)
[Em] Mês de entrada:1710
[Cu] Atualização por classe:171031
[Lr] Data última revisão:
171031
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170815
[St] Status:MEDLINE


  9 / 7082 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28803654
[Au] Autor:Nayeri A; Gluck H; Farber-Eger E; Krishnan S; Shamsa K; Lee M; Wells QS; McPherson JA
[Ad] Endereço:University of California, Los Angeles, Los Angeles, California. Electronic address: Anayeri@mednet.ucla.edu.
[Ti] Título:Temporal Pattern and Prognostic Significance of Hypokalemia in Patients Undergoing Targeted Temperature Management Following Cardiac Arrest.
[So] Source:Am J Cardiol;120(7):1110-1113, 2017 Oct 01.
[Is] ISSN:1879-1913
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:Hypokalemia has been consistently reported as a common occurrence during targeted temperature management (TTM) in comatose survivors of cardiac arrest. We sought to better describe changes in serum potassium throughout the different stages of TTM and to assess for any prognostic significance. We analyzed a prospectively collected cohort of 240 patients treated with TTM following cardiac arrest at a tertiary care hospital between 2007 and 2014. The primary outcome was poor neurologic outcome at hospital discharge, defined as a Cerebral Performance Category score >2. Secondary outcomes included death and recurrent ventricular arrhythmia before hospital discharge. Multivariable logistic regression was used to assess for association of hypokalemia and hyperkalemia with the designated outcomes. During all phases of TTM, hypokalemia and hyperkalemia occurred in 207 (86%) and 77 (32%) of patients, respectively. Hypokalemia occurred in 203 (85%) patients at target temperature, and 25 (10%) patients were hyperkalemic following normothermia. In multivariable logistic regression, hypokalemia was not associated with poor neurologic outcomes or recurrent ventricular arrhythmia. Hypokalemia was associated with reduced odds of death before hospital discharge (odds ratio = 0.36, 95% confidence interval 0.13 to 0.97, p = 0.044). Hyperkalemia was not associated with poor neurologic outcomes, death, or recurrent ventricular arrhythmia.
[Mh] Termos MeSH primário: Temperatura Corporal/fisiologia
Reanimação Cardiopulmonar/métodos
Hipopotassemia/epidemiologia
Hipotermia Induzida/métodos
Sistema de Registros
[Mh] Termos MeSH secundário: Idoso
Feminino
Seguimentos
Mortalidade Hospitalar/tendências
Seres Humanos
Hipopotassemia/sangue
Hipopotassemia/etiologia
Incidência
Masculino
Meia-Idade
Razão de Chances
Parada Cardíaca Extra-Hospitalar/mortalidade
Parada Cardíaca Extra-Hospitalar/fisiopatologia
Parada Cardíaca Extra-Hospitalar/terapia
Prognóstico
Estudos Retrospectivos
Sódio/sangue
Estados Unidos/epidemiologia
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
9NEZ333N27 (Sodium)
[Em] Mês de entrada:1709
[Cu] Atualização por classe:170914
[Lr] Data última revisão:
170914
[Sb] Subgrupo de revista:AIM; IM
[Da] Data de entrada para processamento:170815
[St] Status:MEDLINE


  10 / 7082 MEDLINE  
              first record previous record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28739329
[Au] Autor:Negro A; Rossi GM; Nicoli D; Versari A; Farnetti E; Santi R; De Pietri S
[Ad] Endereço:Internal Medicine and Hypertension Unit, IRCCS-Arcispedale Santa Maria Nuova, Reggio Emilia, Italy.
[Ti] Título:Peptide Receptor Radionuclide Therapy-Induced Gitelman-like Syndrome.
[So] Source:Am J Kidney Dis;70(5):725-728, 2017 Nov.
[Is] ISSN:1523-6838
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:Peptide receptor radionuclide therapy (PRRT) is a molecular-targeted therapy in which a somatostatin analogue (a small peptide) is coupled with a radioligand so that the radiation dose is selectively administered to somatostatin receptor-expressing metastasized neuroendocrine tumors, particularly gastroenteropancreatic. Reported toxicities include myelotoxicity and nephrotoxicity, the latter manifesting as decreased kidney function, often developing months to years after treatment completion. We present a case of PRRT-induced kidney toxicity manifesting as a severe Gitelman-like tubulopathy with preserved kidney function. Because profound hypokalemia and hypocalcemia can lead to life-threatening arrhythmias, we highlight the necessity for careful monitoring of serum and urine electrolytes in patients receiving PRRT.
[Mh] Termos MeSH primário: Síndrome de Gitelman/induzido quimicamente
Neoplasias do Íleo/radioterapia
Tumores Neuroendócrinos/radioterapia
Octreotida/análogos & derivados
Compostos Organometálicos/efeitos adversos
Desequilíbrio Hidroeletrolítico/induzido quimicamente
[Mh] Termos MeSH secundário: Acidose/induzido quimicamente
Acidose/metabolismo
Acidose/terapia
Idoso
Calcitriol/uso terapêutico
Carbonato de Cálcio/uso terapêutico
Quimiorradioterapia Adjuvante
Procedimentos Cirúrgicos do Sistema Digestório
Hidratação
Síndrome de Gitelman/metabolismo
Síndrome de Gitelman/terapia
Seres Humanos
Hipocalcemia/induzido quimicamente
Hipocalcemia/metabolismo
Hipocalcemia/terapia
Hipopotassemia/induzido quimicamente
Hipopotassemia/metabolismo
Hipopotassemia/terapia
Sulfato de Magnésio/uso terapêutico
Masculino
Octreotida/efeitos adversos
Vitaminas/uso terapêutico
Desequilíbrio Hidroeletrolítico/metabolismo
Desequilíbrio Hidroeletrolítico/terapia
[Pt] Tipo de publicação:CASE REPORTS; JOURNAL ARTICLE
[Nm] Nome de substância:
0 ((177lutetium-DOTA(O)Tyr3)octreotate); 0 (Organometallic Compounds); 0 (Vitamins); 7487-88-9 (Magnesium Sulfate); FXC9231JVH (Calcitriol); H0G9379FGK (Calcium Carbonate); RWM8CCW8GP (Octreotide)
[Em] Mês de entrada:1710
[Cu] Atualização por classe:171030
[Lr] Data última revisão:
171030
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170726
[St] Status:MEDLINE



página 1 de 709 ir para página                         
   


Refinar a pesquisa
  Base de dados : MEDLINE Formulário avançado   

    Pesquisar no campo  
1  
2
3
 
           



Search engine: iAH v2.6 powered by WWWISIS

BIREME/OPAS/OMS - Centro Latino-Americano e do Caribe de Informação em Ciências da Saúde